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The public procurement segment is one of the components of the pharmaceutical market in Russia. 
Procurement of medicines and medical devices is the top sector of public procurement, both in 
terms of their number and the amount of contracts concluded. The procedure for concluding state 
contracts itself is spelled out in sufficient detail in the regulatory documents, but, despite this, risks 
may arise when concluding a state contract both for a potential applicant for a state order and for a 
state customer. The purpose of the study is to determine the possible risks when concluding a state 
contract of a healthcare institution for medicines and medical devices and ways to reduce them.  
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El segmento de contratación pública es uno de los componentes del mercado farmacéutico en 
Rusia. La adquisición de medicamentos y dispositivos médicos es el principal sector de la 
contratación pública, tanto por su número como por la cantidad de contratos celebrados. El 
procedimiento para concluir contratos estatales en sí mismo se detalla con suficiente detalle en los 
documentos reglamentarios, pero, a pesar de esto, pueden surgir riesgos al concluir un contrato 
estatal tanto para un solicitante potencial de una orden estatal como para un cliente estatal. El 
propósito del estudio es determinar los posibles riesgos al concluir un contrato estatal de una 
institución de salud para medicamentos y dispositivos médicos y las formas de reducirlos. 
 
Palabras clave: riesgo, contrato estatal, medicamentos (medicamentos), sistema de contratación 




The pharmaceutical market for the production and sale of medicines in the Russian 
Federation has its own characteristics. State and municipal purchases of medicines are allocated to 
a rather specific industry, which has a narrow profile. In this market, there are a relatively small 
number of companies with their own specialized assortment, such as cancer drugs, insulins, 
hospital antibiotics, etc., and other dealers do not work with this assortment. 
 
One of the most stable sources of income for the pharmaceutical market is the state order, 
which includes hospital purchases and preferential drug provision. In 2019, suppliers, as well as 
performers and contractors, including those registered in the Unified Register of Procurement 
Participants, submitted 773 applications for participation in procurement under the national project 
"Healthcare". The State program "Development of Healthcare" ranks second after the state 
program "Development of the Transport system" in terms of the total cost of concluded contracts. 
In 2019, 180,737 contracts were concluded, for a total amount of 621,132,793,960 rubles, 
including 9,119 contracts were concluded within the framework of the national project 
"Healthcare", for the amount of 96,978,686,273 rubles. (https://minfins.gov.ru/ru/perfomance). 
 
Since medicines are a specific product that has a number of features that affect the state of 
health and quality of life of people, this type of state contracts is particularly close attention. 
Moreover, in this case, we are talking about budget organizations, and economic risks are also 




The study used the following methods: analysis of the problem and the subject of the study, a 
holistic approach to the study of public procurement management in the field of medicine, the 
study of sources, and methods of empirical research: analysis and synthesis, methods of 
systematization and classification of theoretical and practical data. 
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Any risk is associated with a significant number of factors that influence the decisions made by the 
participants of public procurement. And, despite the fact that the procedure for concluding state 
contracts is spelled out in sufficient detail in the regulatory documents, risks in concluding a state 
contract may arise both for a potential applicant for a state order and for a state customer. 
 
Among the risks at the conclusion of a state contract, two main groups can be 
distinguished: risks before the conclusion of the contract and possible risks at the stage of contract 
execution (Table 1). 
 
Table 1. Classification of risks at the conclusion of a government contract 
Before signing the contract During the execution of the contract 
liquidity risk in the case of signing the 
contract with the insolvent or incompetent 
contractor 
the risk of reducing the profitability of the transaction 
or the occurrence of unforeseen expenses 
the risk of nonperformance of the contract, 
after award of the contract, the counterparty 
waives its execution 
the risk of additional losses, both direct and indirect 
the risk of unfair competition the risk of various disagreements between the partners 
during the implementation of the transaction 
the risk of invalidity of the concluded contract 
short supply as a risk 
the delivery delay as a risk or a premature delivery 
financial or foreign exchange risk 
the risk of inflation 
non-payment by the customer of the delivery or late 
payment as a possible risk 
 
In addition, all types of risks that may arise both at the stage of concluding and 
implementing government contracts can be classified into groups: 
 
1. From the state of the customer's risks include the following possible situation: the 
counterparty is insolvent partner, after the auctions, from signing of the contract refuses 
counterparty, the failure by the counterparty of its contractual obligations, or they are incomplete 
or improperly performed the obligation, the possible ways overestimation of the initial contract 
price not specified partner with the additional costs of performing its contractual obligations; 
 
2. On the part of the supplier or the contractor of the order, the following risks occur: the 
financing was made within a different time frame than specified in the contract; the market 
situation changed in an unfavorable direction; erroneous or incorrect interpretation of the 
provisions of the tender documentation; 
 
3. Both the state customer and the contractor also have certain risks, namely: first of all, it 
is a corporate risk; the risk of corruption; in the bidding process, there may be such a risk as the 
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Figure 1. Main types of risks in public procurement 
 
Government procurement remains one of the most attractive financial sources, but antitrust 
risks are becoming quite high. According to the Federal Antimonopoly Service (FAS), the number 
of cartel collusions and revealed facts of anti-competitive agreements for the supply of medical 
devices and medicines is in second place. The facts of collusion in the procurement of medicines 
and medical products were revealed in 82 regions. The fact that the healthcare sector ranks second 
in terms of government orders and uncovered anti-competitive agreements confirms the high 
antitrust risks. The risks of violating the antimonopoly legislation at the auction are very 
significant and can greatly shake the reputation of the company, lead to multimillion-dollar fines, 
but also contain clear risks of criminal prosecution. 
 
The FAS of Russia is constantly working to identify violations in this area, regularly 
reporting on the introduction of new fines for participants in collusions, the initiation of criminal 
cases in the field of procurement of medicines and medical devices. 
 
One of the largest fines, for example, was paid at the end of 2018 to LLC, the Russian 
pharmaceutical company "PHARM SKD", which is a distributor with its own logistics structure, in 
the amount of more than 85 million rubles. During the investigation, a cartel was revealed for the 
supply of medicines, medical devices, disinfectants and medical nutrition. Moreover, if, in 
accordance with Article 20.35 of the Code of the Russian Federation on Administrative Offenses, 
LLC "PHARM SKD" would not pay this fine on time, it would have to pay the amount in double 
amount. 
 
As examples of successful cooperation between FAS Russia and the law enforcement 
authorities can consider the following: 
– Investigative Committee of Russia in Samara region was indicted and sent to court a 
criminal case in which former Deputy Minister of health of the Samara region A. S. Navasardyan 
and others were charged with bid rigging and the commission of crime, provided by part 3 of 
article 30, part 2 - article 178, part 3 of article 204, part 1 of article 286 of the criminal code; 
 
the inquiry by the Investigation Department of the MIA of Russia, a criminal case under 
part 4 of article 159 of the criminal code against the former Minister of health of the Republic of 
Dagestan I. T. Ibraimova, the results of which revealed the fact of collusion with bidders for the 
purchase of medicines, medical equipment and medical products with embezzlement of budget 
funds; 
 
– investigation Investigation Department of the MIA of Russia in Novosibirsk region 
criminal case under part 2 article 178 of the criminal code of the Russian Federation on the 
conclusion and implementation of LLC "Kompaniya Fitorodnik" and LLC "Terra Medica" 
conspiracy to participate in auction on delivery of medical products and medicines for the needs of 
the Federal State Budgetary Institution "National Medical Research Center named after 
academician Meshalkin". As a result, collusion was revealed when participating in 450 auctions, 
the results of which revealed the facts of illegal profit-making in the amount of more than 580 
million rubles.  
 
Analyzing such cases, the fact of antitrust risks that occur in the supply of medicines is 
Risks in public procurement 
 





Risk of corporatism, unfair competition and 
corruption during the bidding process 
Risk of damage to third parties 
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confirmed. As we can see, the defendants in such cases are not only officials, but also the chief 
doctors, the staff of medical institutions that in one way or another provide "services" to win the 
auction. Antimonopoly risks also apply to the heads of commercial organizations for organizing 
cartel collusions with customers or government agencies. 
Therefore, we see that the main antitrust risks encountered in the activities of 
pharmaceutical companies can be: 
- cartels and anti-competitive agreements; 
- various types of abuse of a dominant position, as a result of which unfavorable terms of 
transactions are imposed on counterparties; 
- unreasonable from an economic point of view, the pricing; 
- bidding in violation of antitrust laws; 
- unfair competition; 
- violation of the requirements and legislation in the field of advertising. 
It is possible to significantly reduce such antitrust risks by introducing antitrust compliance 
in the organization, which consists in compliance with internal and external requirements, 
regulations and norms. Antimonopoly compliance is the most effective mechanism aimed at 
reducing antimonopoly risks and violations of legislation in this area, and in the event of cartel 
collusions, the risks of possible crimes are also reduced. 
 
The main objectives of compliance are measures to identify, prevent and eliminate various 
risks through the tools of compliance control. Among the main tools of compliance control, we can 
distinguish such as: local regulatory acts regulating the compliance control system; a system for 
detecting violations of the law and informing about such violations; within the framework of 
compliance control, conducting training with this system and testing; in case of detection of 
violations of the law, conducting investigations of compliance procedures; this system provides 
both incentives and penalties in the event of violations, as well as the inclusion of mandatory 
clauses in contracts that are of an antitrust nature. 
Compliance risks are possible if the following reasons are identified: 
- ignorance of legal acts and prohibitions that lead to uncompetitive behavior; 
- in the absence of rules for the clear selection of counterparties and further work with 
them; 
- when the rules of working with contractors are violated; 
- lack of coordination of actions for the release of advertising materials with legal services; 
- the pricing system does not comply with the antimonopoly legislation. 
 
Even if you are fully prepared to implement compliance control in the organization, you 
should pay very close attention to the development and implementation of this technology.The 
scope of compliance control tools is significant, it is necessary to know all the subtleties and 
requirements of the legislation, and a big mistake is made by companies that try to cope with such 
a volume of work on their own. It is important to know the stages and stages of implementation of 
a particular project, and ignorance can lead to additional costs and losses.If the organization does 





The analysis of risks at the conclusion of state contracts shows that any economic activity, 
including the activities of budgetary institutions of the health system, is associated with certain 
types of risks. Tasks to prevent and minimize risks should be aimed at a more detailed study of 
existing and potential partners; monitoring prices at the stage of order formation; thorough study of 
all regulatory, tender and technical documentation, if necessary, the conclusion of contracts for 
legal support of the transaction; automation of order placement procedures, the use of electronic 
auctions, which makes procurement activities more open and transparent. 
 
Pharmaceutical company, using a system of compliance control in their activities, in case 
of violation of norms of the Federal law "On protection of competition" dated 26.07.2006 No. 135-
FZ "On combating corruption" dated 25.12.2008 No. 273, can avoid administrative and criminal 
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sanctions, both in terms of the organization and its employees to help protect business reputation 
of the organization to contractors and public authorities. 
Of course, the choice between activities to minimize antitrust risks carried out by the 
structural divisions of the company itself or with the involvement of specialists in this field is 
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